Structurally unique PARP-1 inhibitors for the treatment of prostate cancer

Area of Science:

• Oncology
• Medicinal Chemistry
• Drug Discovery

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis.
• Poly(ADP)-ribose polymerase-1 (PARP-1) inhibitors are effective in some prostate cancers, but resistance limits treatment options.
• Novel therapeutic strategies are needed for patients unresponsive to current treatments.

Purpose of the Study:

• To identify novel small molecules with Poly(ADP)-ribose polymerase-1 (PARP-1) inhibitory activity for potential mCRPC treatment.
• To reduce a large library of PARP-1 inhibitors to a select group with favorable drug-like properties.
• To establish a pipeline for preclinical development of promising anti-cancer compounds.

Main Methods:

• Employed an integrated screening strategy combining cellular assays, informatics, and in silico computational approaches.
• Utilized dose-response testing to evaluate compound efficacy within a specific concentration range.
• Filtered 664 validated PARP-1 inhibitors based on physicochemical/ADME properties, chemical uniqueness, and off-target effects.

Main Results:

• Successfully reduced the library of 664 PARP-1 inhibitors to 9 unique small molecules.
• The selected 9 molecules exhibit favorable physicochemical/ADME profiles and dose-responsivity (1–20 µmol/L).
• These compounds possess unique chemical fingerprints and low similarity to existing drugs, suggesting novel mechanisms or reduced cross-resistance.

Conclusions:

• The integrated screening approach effectively identified 9 novel PARP-1 inhibitor candidates.
• These 9 molecules are suitable for further preclinical evaluation, including in vitro and in vivo studies.
• This strategy provides a promising pathway for developing new therapies for advanced prostate cancer.